Portola Pharmaceuticals Inc. (PTLA) announced Monday morning that its Phase 3 study of ANNEXA(TM)-R met all primary and secondary endpoints with high statistical significance.
Portola Pharmaceuticals also reported a fourth quarter net loss of $0.82 per share, compared to the loss of $0.63 a year ago. The consensus estimate was for a loss of $0.90 per share.
Portola Pharmaceuticals gapped up at the open Monday and has risen sharply in early trade. The stock is now up 3.42 at $41.50 and has climbed to a new high for the year.
For comments and feedback contact: editorial@rttnews.com
Business News